Identification and characterization of residual melanoma cells to MAPL-targeted therapy: a search for biomarkers and novel therapeutic opportunities Ghent University
Melanoma is one of the most aggressive and treatment-resistant human cancers. 50 to 70% of melanomas carry BRAF mutations, with BRAFv600E being the most abundant. BRAF v600E which results in constitutively overactive MAPK/MEK/ERK signaling and melanocyte hyperproliferation, has been successfully exploited for targeted therapy. Selective RAF inhibitors such as vemurafenib or dabrafenib showed an unprecedented antitumor response rate in ...